News and Trends 7 Nov 2016Results from 45% of Clinical Trials are kept Secret A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported.… November 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2016Roche hits a Speed Bump on the way to a Hemophilia Cure The Swiss pharma is gearing up for a battle with Novo Nordisk in Hemophilia, but a safety setback might slow… November 4, 2016 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug Sanofi and Regeneron (NY, US) have ruled their phase III clinical trial immunotherapy Sarilumab a huge success. Now awaiting US… October 31, 2016 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2016The ‘First and Only’ Metastatic Lung Cancer Immunotherapy is approved Roche's Genentech has received FDA approval for an immunotherapy targeting the highly sought-after PD-L1. The treatment may be able to… October 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2016Big Pharmas Battle to be the Lung Cancer Leader at ESMO Merck, Roche and BMS have unveiled updated results in Copenhagen as the companies duke it out for the leadership in… October 10, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2016German Biotech allies with Genentech in battle for Cancer Vaccine BioNTech has turned up the heat in the race to bring an mRNA immunotherapy for cancer to the clinic. The… September 21, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2016Roche’s New Antibody is besting the best MS Drug Roche is poised to blow away the competition for the new multiple sclerosis drug with its leading candidate, Ocrevus (ocrelizumab).… September 15, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2016Roche drops Partnership for Hepatitis Immunotherapy While everybody wants to get the next immunotherapy on the market, Roche is turning its back on one. It's leaving… August 4, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2016Roche debuts new MedTech for needle-free management of Diabetes Roche is making progress in its Diabetes Care unit. It has struck a deal with the MedTech company Senseonics to… May 30, 2016 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 18 Mar 2016Roche signs a €900M deal with an Immunotherapy Biotech in Boston Roche (Switzerland) has picked 5 candidates from Blueprint Medicines (US) to complement its leading oncology pipeline. Roche is a leader… March 18, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2015Squeezing Cells: A Revolutionary Cancer Drug Delivery Platform for €455M? The MIT spin-off SQZ Biotech has an invention (Cell SQueeZe) which could make vector drug delivery in Cancer a thing of… December 9, 2015 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2015#Sorry: The World-leading Oncology Company fails in Phase III Antibody Drug Conjugate is a smart way to improve chemotherapy. That is the strategy of Roche / Immunogen's drug Kadcyla®, which… October 23, 2015 - 2 minutesmins - By Jerome Topsent Share WhatsApp Twitter Linkedin Email
News and Trends 14 Oct 2015No, Novartis and Roche won’t merge (yet)! Novartis already owns 33% of Roche, but even if both companies are headquartered in the same city of Basel (Switzerland),… October 14, 2015 - 2 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2015Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis Adheron Therapeutics is a small California (US) biotech which has developed a phase I monoclonal antibody (mAb) therapy for inflammatory… October 12, 2015 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 9 Oct 2015TauRX, the leading Alzheimer-focused Biotech, earns funding after Phase II breakthrough The Tau protein has already been implicated in the onset of Alzheimer's, with many biotechs on the hunt for a… October 9, 2015 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2015What Happened this Week? Abbvie abandons Galapagos, CRISPR Patent war to end and AI to exploit UK’s 100k genomes Monday: AbbVie abandons Galapagos phase III and stock plummets 39% (and still dropping) Tuesday: Will Roche lose it’s Worldwide Leading position in… October 3, 2015 - 1 minutemin - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2015Will Roche lose its Worldwide Leading position in Cancer treatments? Roche is the worldwide leader in cancer treatments, but it's threatened by the increasing competition of biosimilars and the development… September 29, 2015 - 4 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 25 Sep 2015Roche’s patent halts an Amgen biosimilar debut Amgen has had great success with its Avastin biosimilar, used as an inhibitor of angiogenesis in tumor growth. However, despite… September 25, 2015 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2015Roche adds AveXis to its SMA portfolio – determined to dominate market Swiss Roche is looking to dominate market in Spinal Muscular Atrophy (SMA) research, now also investing in AveXis as part… September 10, 2015 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2015Genentech’s Sean Bohen defects to AstraZeneca as CMO AstraZeneca's Senior management team gets reinforced by Sean Bohen, a top executive from Roche's subsidiary Genentech. Starting in two weeks,… September 1, 2015 - 2 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email